Cross-talk between nicotinic acetylcholine (nAChR) and serotonin (5HT3R) receptors in sympathetic neurons by Wong, Andy
CROSS-TALK BETWEEN NICOTINIC ACETYLCHOLINE (NACHR)  
AND SEROTONIN (5HT3R) RECEPTORS IN SYMPATHETIC NEURONS 
 
 
 
A Thesis Submitted to the College of 
Graduate Studies and Research 
In Partial Fulfillment of the Requirements 
For the Degree of Master of Science 
In the Department of Physiology 
University of Saskatchewan 
Saskatoon 
 
By 
 
Andy W. L. Wong 
 
 
 
 Copyright Andy W. L. Wong, August 2013. All rights reserved. 
i 
 
PERMISSION TO USE 
In presenting this thesis in partial fulfilment of the requirements for a Postgraduate degree from 
the University of Saskatchewan, I agree that the Libraries of this University may make it freely 
available for inspection.  I further agree that permission for copying of this thesis in any manner, 
in whole or in part, for scholarly purposes may be granted by the professor or professors who 
supervised my thesis work or, in their absence, by the Head of the Department or the Dean of the 
College in which my thesis work was done.  It is understood that any copying or publication or 
use of this thesis or parts thereof for financial gain shall not be allowed without my written 
permission.  It is also understood that due recognition shall be given to me and to the University 
of Saskatchewan in any scholarly use which may be made of any material in my thesis. 
 
 Requests for permission to copy or to make other use of material in this thesis in whole or 
part should be addressed to: 
 
 
 Head of the Department of Physiology 
 University of Saskatchewan 
 Saskatoon, Saskatchewan S7N 5E5 
 
 
 
 
ii 
 
ABSTRACT 
Serotoninergic type 3 receptors (5HT3Rs) are members of the Cys-loop family of ligand-
gated ion channels (LGIC), which includes nicotinic ACh, glycine, GABA-A and GABA-C 
receptors. All members of this family are widely expressed in the central and peripheral nervous 
systems, where they mostly participate in fast synaptic transmission. Activation of 5HT3Rs on 
vagal sensory nerve endings affect respiration, circulation, emesis and nociception; and in the 
central nervous system they are implicated in anxiety, depression, and drug dependence. In 
contrast, the function of 5HT3Rs in sympathetic neurons has not been fully determined. We 
discovered that 5HT3Rs interact with nicotinic acetylcholine receptors (nAChRs), the main 
drivers of the fast cholinergic autonomic synapse, through cross-talk mechanisms. We examined 
cross-talk by the patch-clamp technique on cultured mouse superior cervical ganglia (SCG) 
neurons. Co-stimulation of 5HT3Rs and nAChRs resulted in the generation of a combined 
current that was smaller than arithmetically predicted if the receptors did not interact with one 
another. This interaction, which we quantified as mean peak amplitude and mean ionic charge, 
was dependent on activation of 5HT3Rs and nAChRs, and independent of metabotropic 
receptors, Ca
2+
 entry and Ca
2+
 second messenger pathways, and of the direct action of 5HT on 
nAChRs. Preliminary data using an antibody targeted to the M3-M4 linker region of the 5HT3A 
subunit revealed that 5HT3Rs and nAChRs possibly cross-talk through physical interactions. 
These results revealed a potential role of the 5HT3R in the regulation of sympathetic synaptic 
transmission through cross-talk inhibition of nAChRs. 
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CHAPTER 1  
GENERAL INTRODUCTION 
 
The function of the autonomic nervous system (ANS) is to maintain physiological  
homeostasis. Three autonomic divisions participate in this critical task, including the sympathetic 
(SNS), the parasympathetic (PSNS), and the enteric (ENS) nervous systems. In this thesis we 
will concentrate particularly on function and regulation of the SNS. The SNS is important for 
homeostasis. It modulates a wide variety of body functions, including vascular dynamics, 
sweating, piloerection and temperature control, bronchial dilatation, pupillomotor function, heart 
rate, GI motility, and reproduction (Langley, 1903; Janig and McLachlan, 1992; Boron and 
Boulpaep, 2009). In addition to homeostasis, the SNS plays a pivotal role in the control of the 
body’s immediate adaptations to acute environmental stressors. A classical physiological 
outcome driven by SNS is the “fight-or-flight response” (Jansen et al., 1995). This is triggered by 
a perceived harmful or threatening stimulus. This response causes an increase in heart rate, 
respiration, focus, and overall arousal and energy providing the body with increased strength and 
speed in anticipation of fighting or running (Boron and Boulpaep, 2009). Malfunctions of the 
ANS, or dysautonomia, can compromise multiple organ systems. The symptoms can include 
cardiovascular problems such as resting tachycardia and orthostatic hypotension, metabolic 
disorders such as hypoglycemia unawareness in diabetes, and gastrointestinal (GI) problems such 
as constipation. In patients with long standing diabetes, dysautonomia contributes to the 
manifestation of cardiovascular disease which accounts for up to 80% of premature deaths 
(Canadian Diabetes Association; http://www.diabetes.ca/Section_About/prevalence.asp). The 
key to understanding how the SNS functions in health and disease is to study how it 
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communicates within itself and with the rest of the body. Function and regulation of the SNS is 
mediated by communication through its neurotransmitters and receptors. How a subset of these 
components modulate the SNS is the focus of this thesis.  
 
1.1 Sympathetic Nervous System 
 
1.1.1 Anatomy 
 
 The SNS is one of the three divisions of the ANS, complemented by the parasympathetic 
nervous system (PSNS) and the enteric nervous system (ENS). These systems are autonomic 
because of their abilities to function without modulation from supraspinal centers (Boron and 
Boulpaep, 2009).  
CNS control of the SNS lies in the nucleus tractus solitarii (NTS), but also includes the 
area postrema, ventrolateral medulla, medullary raphe, reticular formation, locus coeruleus, and 
the parabrachial nucleus (Boron and Boulpaep, 2009). The NTS receives and transmits signals 
with the paraventricular nucleus of the hypothalamus, as well as the central nucleus of the 
amygdala (Andresen and Kunze, 1994). It also has peripheral afferents from chemo- and baro- 
receptors from the arteries, heart, lungs, airways, GI system, liver, and tongue. Medial lesion or 
pharmacological blockade of the NTS will affect baroreflex responses in heart rate, blood 
pressure, and sympathetic nerve activity (Andresen and Kunze, 1994).  
 In the SNS, the most important efferent projections from the NTS travel along the 
intermediolateral column of the spinal cord (Andresen and Kunze, 1994; Fig. 1-1).The NTS 
projections within this column synapse onto preganglionic neuronal cell bodies located in the 
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thoracic 1 to lumbar 3 sections (T1 
to L3) of the spinal cord. The 
preganglionic neurons exit the spinal 
cord at the ventral roots, via white 
rami communicantes (myelinated 
fibers), only at sections T1 to L3. 
There are two groups of ganglia that 
the preganglionic neurons synapse onto, 
the left and right sympathetic chains (paravertebral ganglia, shown in Fig. 1-1), flanking each 
side of the spinal cord, and the prevertebral plexus (not shown in Fig. 1-1), consisting of a 
network of interconnecting ganglia and nerve fibers that run adjacent to- and branch alongside- 
major arteries in the abdomen. The sympathetic chains extend beyond their vertebral origins, 
going from the cervical to the coccygeal levels of the spinal cord. This arrangement serves as a 
distribution system that enables preganglionic neurons, which are limited to the thoracic and 
upper lumbar segments, to activate postganglionic neurons organized in autonomic sympathetic 
ganglia that innervate all body segments. However, there are fewer ganglia than there are spinal 
segments because some of the segmental ganglia fuse during development. An example of this is 
the superior cervical ganglion (SCG), which is the first ganglion of the sympathetic chain, and 
represents the fused cervical ganglia of C1 through C4 (Boron and Boulpaep, 2009).  
 The SCG is particularly useful in SNS research because of its large size, ease of access, 
and well characterized physiology (Savastano et al., 2010; Asamoto, 2005; Tubbs et al., 2002). 
The SCG supplies sympathetic innervations to the head and neck, sweat glands in the face and 
forehead, smooth muscle of eyelid, pupillary dilator muscle in iris, gustatory glands, and heart. 
Fig. 1-1. Sympathetic Efferent Pathway. 
(Modified with permission from Chien, 1967) 
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Thus, cultured SCG neurons are an accepted in vitro model to study sympathetic function at the 
cellular level.  
 
1.1.2 SNS Function 
 
 Langley and Anderson (Langley, 1903) first defined the major functions of the SNS (and 
PSNS). Working mainly on cats, they were able to describe SNS anatomy, and showed that that 
the SNS modulates a wide variety of body functions, including vasoconstriction, vasodilatation, 
sweating, piloerection, bronchial dilatation, pupillomotor function, GI motility, and reproduction 
(Langley, 1903; Janig and McLachlan, 1992). Within the same time period (1915), Walter 
Cannon coined the idea that the SNS has generalized effects, especially in comparison to the 
effects of the PSNS (Janig and McLachlan, 1992). 
 Today, many studies have confirmed their findings, and have added considerable details 
to how the system functions (Janig and McLachlan, 1992; Boron and Boulpaep, 2009), including 
blood clotting time, glucose release, insulin secretion, and blood cell mobilization by spleen 
contraction. In addition, we now know the SNS is a ‘diverging’ system, in that the 
postganglionic fibers outnumber the preganglionic fibers by an estimated 200 times, which 
broadens the areas controlled by the signal originating in the brainstem.  
 
1.1.3 Neurotransmitters and Receptors 
 
 Perhaps the most significant advance in the understanding of the SNS was the 
identification of the neurotransmitters and receptors that form the basis of its function. The 
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neurotransmitter systems can be organized into (1) the neurotransmitters and receptors involved 
in synaptic transmission, and (2) the neurotransmitters and peptides involved in modulation of 
SNS functions. 
 One of the main characteristics of the SNS is that the synapse between the preganglionic 
neuron and the postganglionic neuron at the sympathetic ganglia is cholinergic, while the 
synapse between the postganglionic neuron and the target tissue is adrenergic (Lundberg, 1996). 
The effects caused on the target tissue depend on the type of receptors that that tissue expresses 
(Boron and Boulpaep, 2009).  
The effect of noradrenaline and adrenaline on the target tissue is mediated by multiple 
types of adrenergic receptors (AR) (Boron and Boulpaep, 2009). There are two main types of 
adrenergic receptors, α and β, with different patterns of expression and function. All adrenergic 
receptors are G-protein coupled receptors, with α1-ARs activating phospholipase C (PLC) and 
α2-ARs acting through inhibitory G-proteins (Gαi). The β-ARs (β1-, β2-, and β3-ARs) all act 
through Gαs protein and have distinct tissue distribution. The β1-ARs are highly expressed in the 
heart, where their activation increases cardiac output. The β2-ARs are highly expressed in the 
lungs, where they relax the smooth muscle in the airways. The β3-ARs are expressed mainly in 
adipose tissue, where they are involved in lipolysis (Boron and Boulpaep, 2009).  
As mentioned before the synapses in the sympathetic chain are cholinergic and driven by 
the release of acetylcholine (ACh), which activates nicotinic ACh receptors (nAChR) and 
muscarinic ACh receptors in the postganglionic neuron. nAChRs are ligand-gated ion channels 
(LGIC) that are cation permeable (Na
+
, K
+
, and Ca
2+
), and are responsible for the excitatory 
postsynaptic currents (EPSC) that drive SNS ganglionic transmission (section 1.2.2 describes 
this in more detail). This differs from muscarinic ACh receptors (and ARs), which are G-protein 
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coupled receptors (GPCR). There are three main types of muscarinic receptors expressed in 
sympathetic ganglia, the M1, M2, and M3 subtypes. M1 receptors are present in the postsynaptic 
membrane and facilitate ganglionic transmission through PLC activation. M2 receptors are Gαi 
coupled and are present on the presynaptic membrane where they are responsible for negative 
feedback regulation. M3 receptors are present in the smooth muscle of sweat glands and 
stimulate secretion through PLC activation (Lundberg, 1996; Boron and Boulpaep, 2009).  
There are a couple of exceptions to the SNS functional organization described above. In 
the case of the sweat glands, the postganglionic fibers are cholinergic like the preganglionic 
fibers. The second case is in the adrenal medulla where preganglionic neurons synapse onto 
chromaffin cells, which take on the role of postganglionic neurons. These cells primarily release 
adrenaline (Boron and Boulpaep, 2009).   
There are numerous other neurotransmitters and neuromodulators which “tune” SNS 
function. These transmitters have classically been called the non-adrenergic non-cholinergic 
(NANC) transmitters and they include vasoactive intestinal peptide (VIP), substance P (SubP), 
calcitonin gene related peptide (CGRP), numerous tachykinins, histamine (Hist), nitric oxide 
(NO), ATP, and neuropeptide Y (NPY). These transmitters can be responsible for co-inducing 
vascular smooth muscle contraction, such as with ATP release in postganglionic terminals onto 
ionic purinergic P2X or G-protein coupled P2Y receptors (Lundberg, 1996). NANC transmitters 
can also be responsible for inducing vasodilation, such as in the case of the gaseous transmitter 
NO, synthesized by the enzyme nitric oxide synthase (NOS) from L-arginine (Lundberg, 1996). 
New research is continuing to discover how these NANC transmitters modulate the SNS and 
how they are relevant in SNS disorders.  
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1.1.4 Modulation and Disease 
 
 The SNS is commonly known as the “fight-or-flight system”, but its function extends 
beyond extreme circumstances. The SNS is constantly working such as during eating, exercise, 
or sex. The SNS actively helps to regulate body temperature, deal with visceral pain, control 
bladder and bowel movements, and trigger emesis during nausea. Other factors, such as stress, 
anxiety and fear can significantly influence SNS function. This complexity requires fine control, 
which is mediated by a large number of neurotransmitters and peptides, and their respective 
receptors. Thus, examining transmitters and their receptors is a good starting point when 
studying the pathologies of the SNS. The focus of this section and the rest of the thesis will be on 
the receptors within the sympathetic ganglia, and how they are involved in the function and 
dysfunction of the SNS.  
 Normal SNS function is maintained by fast synaptic transmission at sympathetic ganglia, 
which can be detected by the generation of EPSCs mediated by nAChRs on the postganglionic 
neuron. Thus, pathological conditions that target the function of the nAChRs can lead to serious 
autonomic conditions. This occurs in type I and type II diabetes, where the hyperglycemia-
induced accumulation of reactive oxygen species (ROS) in the cytoplasm of postganglionic SCG 
neurons led to autonomic neuropathy in diabetic mice (Campanucci et al. 2010). They found that 
ROS targeted conserved cysteine residues located in the cytoplasmic side of nAChR pores, 
inactivating the channels (Campanucci et al., 2008, 2010). Inactivation of these receptors led to 
depression of autonomic synaptic transmission and the onset of autonomic complications 
associated with neuropathy in diabetes. Animal models expressing nAChRs in which the 
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conserved cysteine residues have been mutated to a non-oxidizing residue (e.g. alanine) were 
resistant to the hyperglycemia-mediated effect (Campanucci et al., 2010). Although nAChRs are 
driving sympathetic transmission, there are other neurotransmitters modulating the function of 
the postganglionic neuron.  
 
1.2 Two Cys-Loop Receptor Family Members: The Nicotinic Acetylcholine and Serotonin 3 
Receptors 
 
 The nAChRs and 5HT3Rs are members of the Cys-loop receptor super-family, which in 
mammals includes the GABAA and glycine ion channels (Lester et al., 2004). These are called 
Cys-loop receptors because of a characteristic 13 amino acid loop formed by a disulfide bond 
between two cysteine residues in the extracellular N-terminal of each subunit (Tsetlin, et al., 
2011; Jackson and Yakel, 1995). All Cys-loop receptors are pentameric structures formed from 5 
homologous or heterologous subunits (Cooper et al., 1991; Lester et al., 2004). Starting from the 
large N-terminal, each subunit crosses the membrane 4 times, with each domain named M1, M2, 
M3, and M4 (Peters et al., 2005). The M2 section of each subunit combines to create the ion 
selective pore of the channels, with the M1-M2 intracellular region in close proximity 
determining conductivity and kinetics (Tsetlin et al., 2011). The M3-M4 intracellular loop is 
particularly large, at 140 amino acids long in the mouse 5HT3A (Maricq et al., 1991). This large 
region is particularly active in channel gating, receptor assembly and trafficking, and as a 
phosphorylation target for kinases such as protein kinase C (PKC) (Peters et al., 2005; Coultrap 
and Manchu, 2002). A few amino acid differences within the M2 filter region split the Cys-loop 
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receptors into two categories: the anion (glycineR, GABAA) and cation (nAChR, 5HT3R) 
selective channels (Gunthorpe and Lummis, 2001).  
 
1.2.1 The 5HT3 Receptor 
 
The 5HT3R is unique amongst 5HT receptors in that it is an ion channel, while the rest 
are metabotropic GPCRs. Of the Cys-loop receptors, it is the most closely related to the nAChR, 
with 27% and 30% amino acid homology with the α2 and α7 nAChR subunits, respectively 
(Jackson, 1995; Noda et al., 1983). 5HT3Rs can be found in the CNS, including the 
hippocampus, striatum, lateral amygdala, area postrema, and NTS, but are mainly found in the 
PNS, such as the myenteric plexus, submucosal plexus, nodose ganglion, SCG, vagus nerve, and 
DRG (Jackson and Yakel, 1995). These channels mediate fast activating and fast desensitizing 
currents (Jackson and Yakel, 1995). In the CNS, they are known to be involved in anxiety and 
emesis; the latter is especially relevant in chemotherapy. Specific antagonists for 5HT3Rs such 
as granisetron, ondansetron, and tropisetron are widely used as anti-emetics in conjunction with 
chemotherapy (Mochizuki et al., 1999; Jackson and Yakel, 1995).  
The pentameric structure of 5HT3Rs can be homomeric, composed of only 5HT3A 
subunits, or heteromeric, composed of the 5HT3A and 5HT3B subunits (Davies et al., 1999; 
Dubin et al., 1999; Hanna et al., 2000). The 5HT3B subunit has ~45% sequence identity with the 
5HT3A subunit, but cannot form a functional homomeric structure (Park et al., 1995). Receptors 
containing the 5HT3A are found in the spinal cord, and peripheral ganglia, while those 
containing the 5HT3B subunit are found in the nodose, superior cervical, trigeminal, and dorsal 
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root ganglia (Morale and Wang, 2002). 5HT3Rs are activated by 5HT and are non-selective 
cation channels, highly permeable to Na
+
, K
+
 and Ca
2+
 ions (Yang et al., 1992).  
The homomeric and heteromeric 5HT3Rs have marked functional differences in ion-
permeabilities, current-voltage relationship, and single channel conductance (Davies et al., 
1999). Ca
2+
 permeability is higher for the homomeric form, which is accompanied by inward 
rectification. In contrast, the heteromeric receptors have more linear current-voltage relationships 
and larger single channel conductances than homomeric receptors (Peters et al., 2005).  
Currently, there is little information regarding the exact source and pattern of release of 
5HT within the sympathetic ganglia. Small intensely fluorescent (SIF) cells within the SCG of 
guinea pigs and rats are known to contain 5HT, and to be regulated by preganglionic cholinergic 
neurons (Kanagawa et al., 1986; Hadjiconstantinou et al., 1982). Thus, the examination of SIF 
cells would be important for understanding the ganglionic circuit. Other sources of 5HT can 
come from the blood that supplies the sympathetic ganglia (Tubbs et al., 2002). Most 5HT within 
blood is synthesized in the enterochromaffin cells of the gut (Gershon, 1999), and absorbed and 
stored by blood platelets (Ohkawa et al., 2005). In fact, free 5HT levels were found to be low in 
serum, at 5.7 ± 3 nM (Hirowatari et al., 2004).    
 
1.2.2 The Nicotinic Acetylcholine Receptor 
 
 The nAChRs have been one of the most heavily studied LGICs in history due to their 
critical function in mammalian physiology, diverse tissue expression, and the flexibility their 
subunit-diversity imparts on receptor function. Our understanding of the structure of Cys-loop 
receptors stems from the study of the nAChR rich electric organ of the Torpedo electric ray 
11 
 
(Brejc et al., 2001; Miyazawa et al., 2003; Unwin, 2005). The nAChRs have major functions in 
both the CNS and PNS. In the CNS, where they are mostly expressed presynaptically, they 
participate in the modulation of hippocampal inhibitory circuitry and dopamine transmission in 
the basal ganglia; while in the PNS, where they are expressed mostly postsynaptically, they are 
involved in receiving motor inputs at neuromuscular junctions and driving autonomic ganglionic 
transmission (Hurst et al., 2013). Similar to 5HT3Rs, these channels mediate fast depolarizing 
currents, carried by Na
+
, K
+
, and Ca
2+
 ions. The nAChRs have been implicated in Alzheimer’s 
disease, Parkinson’s disease, and nicotine addiction (Albuquerque et al., 2009).  
Like other Cys-loop receptors, the structure of the nAChRs is pentameric (Cooper et al., 
1991). In muscles, the nAChRs are mainly composed of 2 different subunit combinations: α1, 
β1, δ, and γ in embryonic muscle, and α1, β1, δ, and ε in postnatal muscle (Saito, 2002). Both 
combinations include two α1 subunits, where the ACh binding pocket is located (Albuquerque et 
al., 2009). In CNS and PNS neurons, there are 7 α subunits (α2-7, 9, 10), and 3 β subunits (β2-
β4) (Albuquerque et al., 2009).Thus far, the α3-5, α7, β2, and β4 subtypes have been identified in 
SCG (Gotti and Clementi, 2004; Rust et al., 1994; Corriveau and Berg, 1993). Most nAChRs in 
the SCG are formed by the heteromeric α3β4 combination (55%), while α3β4α5 and α3β4β2 
correspond to 24% and 21% respectively (David et al., 2010; Skok, 1999; Voitenko, 2001). All 
heteromeric combinations include two α subunits and the only functional homomeric receptors 
are formed by α7 subunits (Skok, 2002; Role, 1999).  
In the SCG, nAChRs are responsible for the generation of fast EPSCs (Derkach et al., 
1983). Currents carried by α3β4-containing receptors show strong inward rectification, caused by 
the pore blocking effect of intracellular spermine at positive potentials (Haghighi and Cooper, 
2000). In addition, nAChRs are known to be highly Ca
2+
 permeable compared to other cations 
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(Trouslard et al., 1993). High Ca
2+
 permeability allows the receptor to activate multiple Ca
2+
 
dependent kinases, including phosphoinositol 3 kinase (PI3K), PKC, protein kinase A, 
calmodulin-dependent protein kinase II (CAM kinase II), and extracellular signal-regulated 
kinases (ERK) (Albuquerque et al., 2009). In addition to these cellular effects of activating 
nAChRs in central and peripheral neurons, they can also interact with other LGICs, such as 
P2X2 receptors. The main focus of this thesis will be to study the functional interaction between 
the nAChRs and 5HT3Rs in sympathetic neurons, and the consequence on SNS function.  
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CHAPTER 2  
CHARACTERIZATION OF 5HT-INDUCED MODULATION OF  
nAChR-MEDIATED CURRENTS 
 
2.1 Introduction 
 
Interaction, or cross-talk, between receptors has been particularly studied in the Cys-loop 
receptor super-family. Both the 5HT3Rs and nAChRs show the ability to interact with other 
LGICs, especially the purinergic P2X receptors. In the guinea pig intestine, and when co-
expressed in Xenopus oocytes, cross-talk between 5HT3Rs and P2X2Rs was revealed by the co-
application of 5HT and ATP, which evoked a current smaller than the addition of individually 
evoked currents (Barajas-Lopez et al., 2002; Boue-Grabot et al., 2003). The mechanism behind 
this effect was determined to be independent of Ca
2+
, receptor phosphorylation, G-protein 
coupling, and GABAc receptors, suggesting a physical receptor-receptor interaction. 
Mutagenesis experiments show that these receptors were interacting at the P2X2 C-terminus and 
the 5HT3 M3-M4 linker (Boue-Grabot et al., 2003, 2004).  
 nAChRs have also been shown to cross-talk with P2XRs in a similar fashion to the 
interaction between P2X2Rs and 5HT3Rs. In both rat SCGs and guinea pig myenteric neurons, 
co-application of ACh and ATP produced smaller currents than were expected if the P2X and 
nAChR receptors worked independently (Zhou and Galligan, 1998; Nakazawa, 1994). 
Experiments in which P2X2Rs and α3β4-containing nAChRs were heterologously co-expressed 
in Xenopus oocytes revealed that P2X2Rs inhibited the opening of nAChRs, and that the effect 
was mediated by physical interaction (Khakh et al., 2000; Decker and Galligan, 2010). 
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 These findings emphasize the ability of the 5HT3Rs and nAChRs to interact with other 
LGICs, and point to the possibility that they interact with each other. nAChRs are essential for 
fast synaptic transmission in autonomic ganglia, and deletion of the α3 subunit, which is the 
highest expressed α-nicotinic subunit in SCGs, abolishes autonomic function in mice (Xu et al., 
1999). Despite not being directly involved in fast synaptic transmission, 5HT3Rs are also 
expressed in the SCG (Tecott et al., 1993; Morales and Wang, 2002), but their contribution to 
autonomic function is still unclear.  
In the current thesis I examined the interaction between 5HT3Rs and nAChRs in primary 
cultures of mice SCG neurons. My findings reveal that these receptors interact with each other, 
possibly through a cross-inhibitory mechanism involving physical interaction. 
 
2.2 Methods 
 
2.2.1 Primary SCG Cultures 
All experiments were approved by the University of Saskatchewan’s Animal Research 
Ethics Board, and adhered to the Canadian Council on Animal Care guidelines for humane 
animal use. Primary SCG from neonatal C57BL/6 mice between postnatal day 1 to 3 (P1-P3) 
were used for the preparation of the dissociated SCG neuron cultures. The methods used to 
dissociate the neurons have been described previously (McFarlane & Cooper, 1992; Campanucci 
et al., 2008). Briefly, mice were euthanized by cervical transection in a sterile environment.  
SCG were collected into a petri dish with serum-containing media (L15 supplemented with 
vitamins, cofactors, penicillin-streptomycin and 5mM glucose, and 10% horse serum). Forceps 
were used to remove the remaining efferent and afferent nerves from the ganglia. Once the 
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ganglia were cleaned, they were enzymatically dissociated (0.1% trypsin; Worthington, 
Freehold, NJ, USA) at 37°C for 30-45min, followed by mechanical dissociation with fire-
polished pipettes.  
The resulting cell suspension was transferred to growth media consisting of L-15 
supplemented with vitamins, cofactors, penicillin-streptomycin, 5% rat serum, 7S Nerve Growth 
Factor (10ng/ml) and 5mM of glucose. The neurons were plated on laminin-coated coverslips, 
which were attached to modified 35mm tissue culture dishes. Cells were maintained at 37°C in a 
95% air and 5% CO2 environment and fed every 3-4 days with fresh growth media. To eliminate 
non-neuronal cells, cultures were treated with cytosine arabinoside (10M; Sigma, St. Louis, 
MO, USA) from day 2 to day 4. Cells were allowed to recover and develop for two weeks, after 
which they were subjected to electrophysiological experiments. 
 
2.2.2 Electrophysiology and Agonist Application 
Agonist-evoked currents were recorded using the whole-cell patch-clamp technique 
(Hamill et al., 1981). All cells were voltage-clamped at -60mV. Membrane currents were 
recorded with a Multiclamp 700A patch-clamp amplifier (Axon Instruments, Molecular Devices 
LLC., Sunnyvale, CA) at room temperature and sampled at 5kHz. Recording electrodes were 
filled with intracellular fluid (ICF) with the following composition (in mM): 60 KAc, 70 KF, 5 
NaCl, 1 MgCl2, 1 CaCl2, 2 MgATP, 10 EGTA, and 10 HEPES, with pH adjusted to 7.2 using 
KOH. The extracellular fluid (ECF) contained the following composition (in mM): 140 NaCl, 
5.4 KCl, 0.33 NaH2PO4, 0.44 KH2PO4, 1 MgCl2, 1 CaCl2, 10 HEPES, and 5 glucose, with pH 
adjusted to 7.4 using NaOH. For calcium free experiments, ECF containing 0mM Ca
2+
/50µM 
EGTA and ICF containing 5mM BAPTA was perfused for 10-15min before recording (Barajas-
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Lopez, 2002). Tetrodotoxin 
(TTX, 0.5µM) was added to 
the ECF to avoid the 
generation of spontaneous 
action potentials.  
Cells were exposed to 
agonists using a three barrel 
pipette controlled by a SF-77B 
fast-step perfusion system 
(Warner Instruments LLC, 
Hamden, CT; Fig. 2-1). 
Agonist application protocols were controlled by pClamp 10 software (Molecular Devices LLC, 
Sunnyvale, CA). ECF perfusion through all three barrels was turned on during recording, with 
each barrel fed by a set of syringe reservoirs containing control and agonist solutions. Perfusion 
was driven by a pressurized system (VPP-6, Warner Instruments LLC, Hamden, CT). Chamber 
fluids were siphoned out at a rate matching that of perfusion. 
 
 
 
 
 
 
 
Figure 2-1. Fast-Step Perfusion System. A three barrel glass 
pipette was used to direct fluid flow over the selected cell. 
Drug application was achieved by stepping pipette over to a 
barrel which was perfusing the agonist (Adapted from Warner 
Instruments). 
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Antagonists Type Receptor Working 
Concentration 
Dose 
Determination 
Company Reference 
Asenapine Anti-psychotic 5HT2 20nM 50-1000nM 
affected *5HT- and 
*ACh-induced 
current amplitude 
and desensitization 
rate 
Sigma – 
A7861 
Meltzer et 
al., 2009 
Methiothepi
n 
Anti-psychotic 5HT1, 
5HT6, 
5HT7 
20nM 50-1000nM 
affected 5HT- and 
ACh-induced 
current amplitude 
and desensitization 
rate 
Sigma – 
M149 
Schoeffter 
et al., 1996 
Atropine Competitive M1-M5 1µM See reference Sigma – 
A0132 
Morishima 
et al., 2013 
MDL 72222 Competitive 5HT3 500nM <500nM does not 
block 5HT3R-
mediated currents 
and 1000nM 
inhibits ACh-
induced current 
Tocris - 
0640 
Fozard, 
1984 
Y25130 Competitive 5HT3 10nM <5nM does not 
block 5HT3R-
mediated currents 
Tocris - 
0380 
Sakamori, 
1992 
Table 2-1. Antagonists. 
*all antagonist concentrations were determined based on agonist concentrations used in thesis 
 
 
 
 
Agonist Type Receptor Working 
Concentration 
Dose Determination Company Reference 
5HT Non-specific, 
endogenous 
Multiple 
5HTRs 
100µM Compared with size of 
current and charge of 
other currents (see 
section 3.1.1) 
Sigma – 
H9523 
Mochizuki 
et al., 1999 
mCPBG Specific 5HT3R 50µM ‘’ Sigma – 
C144 
Kilpatrick et 
al., 1990 
ACh Non-specific, 
endogenous 
Multiple 
AChRs 
15-100µM ‘’ Sigma – 
A6625 
Campanucci 
et al., 2010 
Nicotine specific Nicotinic 
AChRs 
50µM ‘’ Sigma - 
36733 
Hu et al., 
2007 
Table 2-2. Agonists.  
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2.2.3 Statistics and Analysis 
 
 All currents evoked by co-application of agonists were compared to a predicted current. 
The predicted current (always reported in red) was calculated in three steps. First, the ACh and 
5HT currents stimulated before co-application of agonists were added together within Clampfit 
software, and then the peak amplitude or charge of the summated current was measured. Then, 
the same two currents stimulated after co-application were added together, and the peak 
amplitude or charge of the current was measured. Finally, the two peak amplitude values were 
averaged to obtain the predicted current. These calculations took into consideration the typical 
changes in amplitude of the 5HT and ACh-evoked currents.  
 All current peak amplitudes were normalized to the cell capacitance and expressed as 
current density (pA/pF). Ionic charge was calculated as the integrated area under the current 
trace (from 0.2s before agonist onset to 2s after removal) and expressed in nanocoulombs (nC). 
All values were reported as mean ± SEM.  
 We used the paired t-test to compare mean current densities and mean charge, with the 
level of significance set at P < 0.05.  
  
2.3 Results 
 
To test the hypothesis that the nAChRs and 5HT3Rs expressed in SCG neurons were 
involved in cross-talk mechanisms, we used a modified protocol previously described to examine 
cross-talk between 5HT and ATP-evoked currents (Boue-Grabot et al., 2003). To do this, we first 
evoked whole-cell currents by applying ACh and 5HT or the 5HT3R selective agonist methyl-
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chlorophenylbiguanide (mCPBG) separately (for 1s), followed next by the co-application (1s) of 
ACh and 5HT (or mCPBG). At the end of the stimulation protocol we re-probed with 5HT and 
ACh separately as a recovery test. Figure 2-2 outlines these experiments, showing currents from 
representative cells using 5HT (Fig. 2-2A) and mCPBG (Fig. 2-2C). Representative current 
examples show individually stimulated currents before (left), co-applied agonists (center), and 
individual currents (recovery) after co-application of agonists (right). Note the predicted current 
obtained by the addition of the individual evoked currents (for calculation see methods) is 
represented in red (Fig. 2-2A-F).   
As previously described (see section 1.2.1 and 1.2.2) the kinetic profiles of ACh and 
5HT-evoked currents in cultured SCGs were markedly different. While both inward currents 
were fast activating, the ACh-evoked currents were slightly slower than the 5HT-evoked currents 
(David et al., 2010; Solt et al., 2007). In addition, the desensitization phase of the individual 
currents was markedly different, with 5HT-evoked currents desensitizing at a faster rate and 
showing total desensitization by 1-2s (Fig. 2-2). 
It is important to note that to obtain an accurate predicted current we chose agonist 
concentrations that produced currents similar in size. But because currents evoked through each 
receptor type varied in amplitude over the course of an experiment, with ACh-evoked currents 
potentiating (~10%) and 5HT-evoked currents running-down (~25%), we were required to 
compensate for these changes by averaging the currents before and after the co-application of 
agonists to calculate the predicted current. 
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2.3.1 Peak amplitudes of nAChR- and 5HT3R-mediated currents were non-additive  
 
Figure 2-2A shows a representative example where ACh- and 5HT-evoked currents were 
non-additive. The comparison between the actual (black trace) and the predicted (red trace) 
current revealed that the fast desensitization characteristic of 5HT3Rs was absent in the actual 
current. In fact, the kinetics of the actual current resembled that of the nAChR mediated current, 
i.e. with slow desensitization. In addition, the amplitude of the actual current was approximately 
25% smaller than that of the predicted current, suggesting there were cross-inhibitory effects 
between the receptors (Fig. 2-2B, P < 0.001, n = 14 neurons).  
5HT can also activate multiple 5HT-metabotropic receptors (m5HTRs) in SCG neurons, 
which are known to express 5HT1, 5HT2, 5HT3, 5HT6, and 5HT7 receptors (Pierce et al., 
1996). To test whether m5HTRs contributed to the cross-inhibitory effects between ACh- and 
5HT-evoked currents, we used the 5HT3R specific agonist, mCPBG (50µM), instead of 5HT 
(Fig. 2-2C). Under these conditions the actual current was not only smaller than the predicted but 
the effect was more pronounced than when using 5HT, resulting in an actual current 
approximately 40% smaller than the predicted (Fig. 2-2D, P < 0.01, n = 6).  
SCG neurons also express metabotropic (muscarinic) ACh receptors, including M1, M2, 
and M3 subtypes, which have been reported to hyperpolarize or depolarize the neuronal resting 
potential through K
+
 and Ca
2+
 channels (Lundberg, 1996; Boron and Boulpaep, 2009). 
Therefore, to test whether metabotropic receptors contribute to the cross-inhibitory effect we 
next repeated our experiments in the presence of antagonists to block all possible muscarinic 
receptors and m5HTRs naturally expressed in SCG neurons. We used the muscarinic antagonist 
atropine (Atr, 1µM); the 5HT1R, 5HT6R and 5HT7R antagonist methiothepin (Met, 20nM); and 
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the 5HT2R antagonist asenapine (Ase, 20nM). This drug cocktail allowed us to obtain currents 
mediated solely by nAChRs and 5HT3Rs. Consistent with our data showing that 5HT3Rs were 
involved in the cross-inhibition (Fig. 2-2C and 2-2D), the actual currents generated in the 
presence of the antagonist cocktail remained smaller than predicted, suggesting that metabotropic 
receptors were not involved in cross-inhibition (Fig. 2-2E and 2-2F, P < 0.001, n = 15 neurons).  
 
 
22 
 
 
Figure 2-2. nAChR and 5HT3R-mediated currents were non-additive. nAChR- and 5HT3R-
mediated currents were evoked by single or combined application of agonists in cultured SCG 
(A, C & E) Representative example traces, show the characteristics of the individual and 
combined currents used in this experiments. (A & B) The co-application of ACh- and 5HT 
evoked non-additive currents (P < 0.001, n = 14 neurons). (C & D) The co-application of ACh 
and the 5HT3R specific agonist mCPBG  also induced non-additive currents (P < 0.01, n = 6 
neurons). (E & F) The co-application of 5HT and ACh in the presence of the metabotropic 
antagonists atropine (Atr, 1µM), methiothepin (Met, 20nM), and asenapine (Ase, 20nM) evoked 
non-additive currents as well (P < 0.001, n = 15 neurons). All current amplitudes (B, D, F) were 
normalized to cell capacitance (current density, pA/pF) and expressed as mean ± SEM. (* P < 
0.05; ** P < 0.01; *** P < 0.001).  
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2.3.2 Ionic charges conducted by nAChRs and 5HT3Rs were non-additive 
 
 As explained above, the kinetic profiles of the currents mediated by 5HT3Rs and 
nAChRs were markedly different, particularly due to the faster activation and desensitization of 
the 5HT-evoked currents. These differences were not considered when calculating the predicted 
current using peak amplitudes. Therefore, to account for these differences, we calculated and 
compared the ionic charge for each current.  
 To obtain the ionic charge we integrated the area under the curve in a given current trace. 
We calculated the ionic charge from 0.2s before agonist application to 3s after agonist removal, 
inclusive. This time period was chosen to encompass the entirety of the currents. 
As with peak amplitude analysis, the charges conducted by nAChRs and 5HT3Rs were 
non- additive. Figure 2-3A shows representative current traces indicating the difference between 
the actual and predicted currents, which was summarized by plotting the mean ionic charge (Fig. 
2-3B; P < 0.01, n = 8 neurons). In addition, it can be observed that with lower ACh 
concentrations (15µM instead of 50µM), the actual combined current had kinetic features that 
resembled those of the 5HT3R-mediated current (faster activation and desensitization). This 
suggests that although the actual currents obtained by co-application of agonists resembled those 
generated by nAChRs, both receptors contribute to the kinetics of the evoked current and the 
extent of the contribution is determined by the concentration of the agonists.  
The resemblance of the actual combined current to the 5HT3R-mediated current was 
more pronounced when applying mCPBG and ACh, than when using 5HT (Fig. 2-3C and D), 
showing faster activation and desensitization kinetics (Fig. 2-3C). Again the values of the actual 
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ionic charges were significantly less than predicted, with a stronger effect when using mCPBG 
instead of 5HT (Fig. 2-3D, P < 0.001, n = 9 neurons).  
These data indicate that even after accounting for the different current kinetics, the 
5HT3R- and nAChR-mediated currents were still non-additive.  
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Figure 2-3. nAChR and 5HT3R-mediated ionic charges were non-additive. These 
experiments summarize the currents evoked by single and combined applications of agonists 
expressed as ionic charge (area under the curve) calculated from t = 0.8 to 4s. Please note the 
concentration of ACh was lowered to 15µM to obtain comparable 5HT and ACh ionic charges. 
(A & B) The combined application of ACh (15µM) and 5HT (100µM) resulted in significantly 
lower actual charges than predicted (P < 0.01, n = 8). (C & D) The combined charges resulting 
from co-application of the 5HT3R specific agonist mCPBG (50µM) with ACh (15µM) also 
resulted in significantly lower charges than predicted (P < 0.001, n = 9). All data in this figure is 
presented as mean ± SEM, in nanocoulombs (nC). Means are tested with the paired t-test (* P < 
0.05; ** P < 0.01; *** P < 0.001)  
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2.3.3 Activation of 5HT3Rs during extended ACh application induced inhibition of ACh-
evoked currents 
 
 So far we demonstrated that the currents mediated by the two receptors were non-
additive. Next we concentrated on identifying the characteristics of this interaction. In this series 
of experiments, we aimed to examine whether 5HT3Rs inhibit the nAChRs. Unfortunately, the 
possibility that nAChRs inhibit 5HT3Rs was not possible due to the fast desensitization kinetics 
of the latter. To test for 5HT3R inhibition of nAChRs, we designed experiments where 5HT 
(100µM; 1s) was applied during a prolonged (100µM; 5s) ACh-evoked current (Fig. 2-4). 
Charges were compared by integrating the area under the curve. We have arbitrarily selected the 
time from t = 2.25s (immediately when 5HT application begins) to 3.75s (0.5s after 5HT 
removal). This time period allowed us to encompass the entire time course of the depression of 
ACh-evoked currents.  
The results from these experiments supported the previous findings, i. e. 5HT and ACh-
induced currents were non-additive, but also described two aspects of the interaction unseen in 
the 1s application protocol. The first aspect was that application of 5HT during the 
desensitization phase of ACh-evoked currents caused an inhibition. This was clearly seen in the 
combined agonist trace in figure 2-4A. When 5HT was applied during the ongoing ACh-evoked 
currents, not only did the currents not increase, but under this experimental protocol, they 
decreased. The effect was even stronger when using mCPBG to selectively activate 5HT3Rs 
(Fig. 2-4C). A more detailed example of the inhibitory strength of mCPBG on ACh-evoked 
currents is shown in figure 2-4F, where we applied mCPBG for the last 6s of a 7s long 
application of ACh, resulting in an inhibition of approximately 80% of the current. The ionic 
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charge data for 5HT and mCPBG applications are summarized in figures 2-4B and D, 
respectively. The combined actual currents were significantly smaller than the predicted currents 
for both 5HT (Fig. 2-4B, P < 0.05, n = 6) and mCPBG (Fig. 2-4D, P < 0.05, n = 4). To ensure 
that the inhibition induced by activation of 5HT3Rs was not an artifact due to possible 
disturbances in the ACh concentration during the fast-step protocol, we controlled for this by 
removing 5HT (or mCPBG) from the solution reservoir, leaving only ACh. Figure 2-4E shows a 
representative control trace where there was no disturbance of the ACh-evoked current.  
 The second, and puzzling, aspect of the interaction is also depicted in more detail in 
figure 2-4F, where we extended the application of mCPBG in the above protocol to 6s. As 
expected, mCPBG depressed the ACh-evoked current as shown in our previous experiment; 
however, this extended trace shows that the depression does not correspond with the kinetics of 
the mCPBG-evoked current. The mCPBG-evoked current reaches maximal amplitude at the 
beginning of agonist application and decays by desensitization over time (see example trace in 
Fig. 2-3C). Thus, this should result in a stronger inhibition at the beginning of the mCPBG 
application. This was clearly not the case in figure 2-4F, where an inverse effect is shown. Based 
on these puzzling findings, the next set of experiments aimed to further examine the relevance 
5HT and 5HT3Rs to the cross-inhibitory effect between the two receptors.   
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Figure 2-4. Short application of 5HT or mCPBG during a prolonged ACh application 
induced inhibition of ACh-evoked currents. 1s of 5HT (100µM) or mCPBG (50µM) was 
applied during a 5s application of ACh (100µM), 1s after ACh onset. Red traces and bars 
indicate predicted currents. Ionic charges were measured from immediately before 5HT/mCPBG 
application, up to 0.5s after removal (1.5s range). (A & B) Show the depression in prolonged 
(5s) ACh-evoked current caused by 1s application of 5HT, which resulted in significantly less 
charge than predicted (P < 0.05, n = 6 neurons). (C & D) Application of mCPBG also depressed 
ACh-current, indicating that the effect was specific to the 5HT3R. The actual charges were 
significantly less than predicted (P < 0.05, n = 4). (E) Representative example showing the 
control for the perfusion fast-step system, where 5HT was removed from the reservoir containing 
5HT and ACh, leaving only ACh. Note, the lack of depression of the ACh-evoked current in the 
absence of 5HT, indicating the effect was entirely due to 5HT or mCPBG application. (F) 
Prolonged application of mCPBG not only depressed ACh-evoked current, but also this effect 
was inversely related to the 5HT3R-mediated current kinetics.  All data in figure is presented as 
mean ± SEM in nanocoulombs (nC) (* P < 0.05; ** P < 0.01; *** P < 0.001).  
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2.3.4 Does the inhibition of ACh-evoked current require the activation of 5HT3Rs? 
 
Our results summarized in section 2.3.3 suggested that once nAChRs have been 
activated, activation of 5HT3Rs causes the inhibition of the ACh-evoked current. However, the 
inconsistency between the kinetic properties of 5HT3R-mediated currents and the characteristics 
of the inhibition made us wonder whether this effect was indeed mediated by 5HT3Rs or an 
alternative mechanism. To examine if the 5HT- and mCPBG-induced inhibition of ACh-evoked 
currents were dependent on the activation of 5HT3Rs, we next repeated our experiments in the 
presence of 5HT3R selective antagonists. We used two different 5HT3R specific competitive 
antagonists: MDL 72222 (bemisetron, 500nM) and Y25130 (10nM) (Fozard, 1984; Sakamori et 
al., 1992). The antagonists were applied to all perfusion solutions. First we recorded a set of 
control current traces for ACh and 5HT (not shown), followed by recording in the presence of 
the antagonists (see Fig. 2-5). Before recording in the presence of antagonist, we confirmed 
5HT-evoked currents were completely inhibited by the antagonists (not shown). Figure 2-5 
displays representative traces for experiments showing the effect of 1s application of 5HT on 5s 
application of ACh (or nicotine)-evoked currents.  
If 5HT3R activation was indeed mediating the inhibition of ACh-evoked currents we 
would expect that the use of the antagonists would prevent this effect. However, 5HT induced a 
depression in the ACh-evoked currents despite being antagonized by MDL 72222 (Fig. 2-5A and 
B) and Y25130 (Fig. 2-5C and D). Next, to confirm that this inhibitory effect of 5HT was acting 
on nAChRs, we repeated the experiment using the nAChR specific agonist, nicotine (50μM, Fig. 
2-5B and D). These results showed that in the presence of 5HT3R specific antagonists, 5HT 
induced a depression in ACh- and nicotinic-evoked currents.  
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In summary, our results using pharmacological blockers for 5HT3Rs revealed that 5HT 
still caused a marked inhibition of nAChRs. These unpredicted results were only observed when 
5HT was applied during a long ACh-evoked current and contrasts with our previous experiments 
(Fig. 2-2C), in which 5HT3Rs were required to cause the cross-talk effects. Therefore, further 
experiments are required to increase our N values and to evaluate the relevance of this findings, 
as well as to repeat these experiments in the presence of m5HTR antagonists and mCPBG, which 
were conditions not tested thus far that would help to clarify these differences. In the next section 
we will consider an alternative mechanism for this effect, namely if 5HT has a direct effect on 
nAChRs.  
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Figure 2-5. 5HT inhibited ACh and nicotine-evoked currents in the presence of 5HT3R 
antagonists. Two competitive 5HT3R specific antagonists, MDL 72222 (500nM) and Y25130 
(10nM) were applied immediately following control recordings (using the 5s ACh protocol 
discussed previously). Each antagonist was perfused for 2min prior to and during the recording 
of the second set of traces. Confirmation of complete 5HT current blockage was done for every 
cell (not shown). (A & B) In the presence of MDL 72222, which completely inhibited 5HT-
evoked currents, 5HT was still able to inhibit ACh- and nicotine-evoked currents, respectively.  
(C & D) Similarly results were obtained in the presence of Y25130, which completely blocked 
5HT-evoked currents (not shown), yet 5HT still inhibited ACh- and nicotine-evoked currents, 
respectively.   
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2.3.5 Does 5HT act directly on nAChRs? 
 
 Data presented in the previous section suggested that 5HT could directly interact with 
nAChRs without activation of 5HT3Rs. In fact, this possibility has been previously considered in 
rat trigeminal neurons, where 5HT directly inhibited nAChRs in a non-competitive manner (Hu 
et al., 2007). Therefore, to explore the possibility that 5HT directly inhibited nAChRs in SCG 
neurons, we performed a dose response curve for ACh-evoked currents with and without 5HT 
pre-incubation, and in the continuous presence of blockers for muscarinic receptors, m5HTRs 
and 5HT3Rs.  
 Using the experimental protocol previously described by Hu et al. (2007), we first 
exposed the cell to ACh and 5HT individually without any antagonists, demonstrating the 
expression of these receptors (see Fig. 2-6A for diagram of experiment). Next, we perfused the 
cell with Atr (1µM), Met (20nM), Ase (20nM), and MDL72222 (500nM), blocking all 
muscarinic receptors, m5HTRs and 5HT3Rs. After 2min, ACh and 5HT-evoked currents were 
re-probed to check for both normal ACh-evoked currents and complete blockage of 5HT3R. 
After this confirmation, we bathed the cell in 5HT (100µM) for 5min. Next, we stimulated the 
cell with ACh again to check for any current changes. Following this, we removed 5HT and 
allowed nAChRs to recover, after which we applied ACh one last time to test for recovery. The 
3
rd
 ACh trace was compared to the average of the 2
nd
 and 4
th
 ACh-evoked traces in each 
experiment (see Fig. 2-6A). The entire process was repeated for 10, 100, and 1000µM 
concentrations of ACh (Fig. 2-6B), and the results were plotted onto a dose response chart. 
Remarkably, our data indicated there was no significant changes between the dose 
responses obtained with or without 5HT (Fig. 2-6C; P > 0.05; 10µM, n = 5; 100µM, n = 6; 
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1000µM, n = 4). Although these were preliminary results and they needed to be confirmed by 
increasing not only the N values but also the concentrations tested to properly fit the data to a 
sigmoidal dose response curve, it is important to note that the concentration range tested here 
corresponds to the one showing marked differences in trigeminal neurons (Hu et al., 2007). 
Therefore, our findings suggest that different mechanisms to those described in trigeminal 
neurons underlie the cross-inhibition of ACh-evoked currents in SCG neurons. 
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Figure 2-6. 5HT did not act directly on nAChRs. (A) The first ACh- and 5HT-induced 
currents demonstrated normal currents in SCG neuron. Following this, Atr (1µM), Met (20nM), 
Ase (20nM), and MDL 72222 (500nM) were perfused onto the neuron to eliminate muscarinic 
AChRs, m5HTRs and 5HT3Rs. Next, 2min after this perfusion, the ACh and 5HT-evoked 
currents were tested again demonstrating that 5HT3R-mediated currents were eliminated and 
nAChR-mediated currents were intact. This was then followed by a 5 min application of 5HT 
(100µM) and next by ACh. This 3
rd
 trace of ACh was expected to be inhibited if 5HT directly 
interacts with nAChRs. The final ACh current was obtained 2min after 5HT removal as 
recovery. For analysis, the average of the 2
nd
 and 4
th
 traces (red in B and C) was compared to the 
3
rd
 trace (black in B and C). (B) Example traces from 10, 100, and 1000µM ACh. (C) Dose 
response comparison between currents recorded with and without 5HT show no difference at all 
three concentrations of ACh used (P > 0.05 at all points; 10µM, n = 5; 100µM, n = 6; 1000µM, n 
= 4). Current densities are displayed as mean ± SEM.  
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2.3.6 Cross-talk between 5HT3Rs and nAChRs was Ca
2+
-independent
 
 
There is considerable evidence supporting the involvement of Ca
2+
 in the regulation of 
both 5HT3Rs and nAChRs through direct and indirect mechanisms. The M3-M4 intracellular 
loop of both receptors is known to be targeted by the Ca
2+
-dependent PKC. The 5HT3A receptor 
subunit had been shown to be potentiated by PKC (Coultrap and Manchu, 2002), while nAChRs 
were also regulated by PKC in addition to numerous other Ca
2+
-dependent kinases (Albuquerque 
et al., 2009). Increases in extracellular Ca
2+
 also directly regulated both of these receptors, 
inhibiting 5HT3R currents (van Hooft and Wadman, 2002; Niemeyer and Lummis, 2001) and 
increasing the open probability of nAChRs (Amador and Dani, 1995). Moreover, removal of 
extracellular Ca
2+
 eliminated ganglionic long term potentiation (gLTP) in sympathetic ganglia 
(Koyano et al., 1984; Briggs et al., 1985). Finally, recent evidence suggests that cross-talk 
between the 5HT3Rs and nAChRs in CNS presynaptic terminals is mediated through Ca
2+
 or 
Ca
2+
-dependent second messengers (Dougherty and Nichols, 2009).  
Since our findings suggest that 5HT may act through other mechanisms not involving 
direct inhibition of nAChRs, we explored the possibility that Ca
2+
may have contributed to the 
inhibitory effect. To examine the dependence of cross-talk on Ca
2+
, experiments were performed 
in the absence of this cation. To achieve this, neurons were bathed in extracellular solution 
containing 0mM Ca
2+
/50µM EGTA and intracellular (pipette) solutions containing the Ca
2+
 
chelator BAPTA (5mM; Barajas-Lopez, 2002). After achieving the whole-cell configuration, a 
10min period was allowed for BAPTA to diffuse into the cell cytoplasm before recording 
currents. The 1s ACh protocol described in figure 2-2 was used to record ACh- and 5HT-induced 
currents.  
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 Our results showed that Ca
2+
 was not required to induce the cross-talk of ACh-evoked 
current by 5HT (Fig. 2-7). The combined actual current was significantly smaller in amplitude 
than predicted (Fig. 2-7B; P < 0.01, n = 5). Therefore, much like the cross-talk between P2X2Rs 
and 5HT3Rs (Barajas-Lopez et al., 2002; Boue-Grabot et al., 2003), the interaction between 
nAChRs and 5HT3Rs does not seem to depend on Ca
2+
.  
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Figure 2-7. Cross-talk between 5HT3Rs and nAChRs did not require the presence of Ca
2+
. 
The same 1s ACh protocol as described in figure 2-2 was used in this experiment. However, in 
this experiment, Ca
2+
 was removed from the intracellular and extracellular solutions. Cells were 
bathed in extracellular solution containing 0mM Ca
2+
/50uM EGTA and patched with 
intracellular solution containing the Ca
2+
 chelator BAPTA (5mM) (Barajas-Lopez, 2002). After 
achieving whole-cell, 10min was allowed for BAPTA to diffuse into the cytoplasm before 
recording currents. (A) A representative cell recorded without Ca
2+
. The combined actual current 
remained smaller in amplitude than predicted. (B) Current densities of actual and predicted 
currents were analyzed and found to be significantly different (P < 0.01, n = 5). (* P < 0.05; ** P 
< 0.01; *** P < 0.001).  
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2.3.7 Is cross-talk between the 5HT3Rs and nAChRs dependent on physical interaction? 
 
 The data presented so far indicate that the interaction between 5HT3Rs and nAChRs does 
not depend on Ca
2+
, the direct effect of 5HT on nAChRs, or metabotropic receptors. Since it was 
shown that P2X2/5HT3 receptors, and nACh/P2X receptors interact in a physical manner, we 
next examined the possibility that 5HT3Rs inhibit nAChRs through physical interactions 
(particularly with their intracellular domains).  
 Previous reports have shown that the 5HT3Rs and P2X2Rs interact physically at the 
cytosolic M3-M4 linker of 5HT3Rs (Boue-Grabot et al., 2003, 2004). In order to test this, an 
antibody targeted to the M3-M4 linker of the 5HT3A subunit (i.e. amino acids 342-355; 
Alomone Labs.) was used in an attempt to prevent the interaction with nAChRs at that site. The 
antibody was applied through the patch pipette and allowed to diffuse into the cytosol before 
recording. Figure 2-8 includes representative traces of these experiments. The antibody dose 
used here was 1:200, which was the recommended dose for immunocytochemistry and Western 
blotting (Alomone Labs.; Fig. 2-8A), and a more concentrated 1:20 dilution (Fig. 2-8B).  
These data showed that while the combined actual currents were still smaller than 
predicted at 1:200 dilutions (Fig. 2-8A), this effect was less pronounced at 1:20 dilutions (Fig. 2-
8B). More importantly, allowing the antibody more time to diffuse intracellularly (10min) 
decreased this difference making the actual currents similar to the predicted current (with the 
exception of kinetics). Unfortunately, since these were preliminary experiments, there was not 
enough data (n = 3) to statistically analyze actual versus predicted currents. However, this data 
supports for the first time that a physical interaction between 5HT3Rs and nAChRs may be 
responsible for the cross-talk mechanisms described in this thesis.  
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Figure 2-8. The polyclonal antibody against the intracellular M3-M4 linker in the α-5HT3A 
subunit interferes with nAChR and 5HT3R cross-talk. The antibody was diluted in the 
intracellular solution and applied through the patch pipette and allowed 5-10min to diffuse to the 
cytosol before recording. Two antibody dilutions were used: (A) 1:200 and (B) 1:20. A 5min 
diffusion time did not totally prevent the cross-talk between the receptors at either dose, but the 
10min diffusion time minimized the difference between the actual and predicted currents. Note, 
the 1:20 dilution had a stronger effect preventing the interaction between the receptors even at 
5min diffusion time.  There was not enough data collected to compare the means of the 
combined actual and predicted currents.  
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CHAPTER 3 
GENERAL DISCUSSION 
 
 In this thesis we revealed a novel cross-inhibitory mechanism between nAChRs and 
5HT3Rs. Using a specific agonist and multiple antagonists, we showed that the effect was 
specific to nAChRs and 5HT3Rs, and that no metabotropic receptors were required for the cross-
inhibition. In addition, we found that the effect was Ca
2+ 
independent and did not involve the 
previously described direct effect of 5HT on nAChRs (Hu et al., 2007). Rather, here we describe 
a cross-talk mechanism that is possibly mediated by receptor-receptor interaction.  
 
3.1 Experiments and Analysis 
 
3.1.1 Predicting the current 
  
 The key measure of our effect laid in the difference between the combined actual 5HT 
and ACh evoked currents and the one predicted. Thus, the calculation of the predicted current 
was a crucial factor in determining cross-talk between 5HT3Rs and nAChRs. 
Two factors influenced how we calculated the predicted current. First, both 5HT and 
ACh-evoked currents changed in amplitude over time. ACh-evoked currents slightly potentiated 
at the beginning of the experiment, while 5HT-evoked currents ran down continuously over time. 
To account for these changes, the predicted current was calculated by averaging the currents 
occurring before and after the combined application of the agonists. Second, since both of the 
currents had different kinetics, with 5HT having a fast activation and desensitization and ACh 
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having a slower desensitization phase, the peak amplitudes of each current did not occur at the 
same point in time. Thus, the summation of the peak amplitude values would result in an 
inaccurate predicted peak. To address this issue, we used Clampfit software to arithmetically 
combine the obtained single currents to generate a predicted current, resulting in a single larger 
current with different peak amplitude and kinetics. Thus, our method provides a more accurate 
predicted current; however, it is worth noting that this calculation assumes that the ACh and 
5HT-evoked currents changed linearly with time. 
To calculate the predicted current we also considered the contribution of 5HT3Rs and 
nAChRs to the predicted current. For example, if the ACh-evoked current was five times larger 
than the 5HT-evoked current, as was observed in many cells, the predicted current would not be 
statistically different than the individual ACh-evoked current. Therefore, in order to make the 
calculation of the predicted current more reliable, we emphasized the difference between the 
actual and predicted currents by adjusting the concentrations of ACh and 5HT/mCPBG to 
produce currents similar in amplitude or charge.  
 
3.1.2 The interaction between 5HT- and ACh-evoked currents 
 
It initially seemed by examining figure 2-2A and B that there was cross-talk occurring 
between ACh- and 5HT-evoked currents. We originally used the peak amplitudes of the evoked 
currents to calculate and compare the actual vs. predicted currents generated by co-application of 
agonist. However, the accuracy of this method was questionable mainly due to the marked 
difference in current kinetics for these two receptors. Due to the fast activation and 
desensitization of 5HT3R-mediated currents vs. the slower activation and desensitization of 
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nAChR-mediated currents, the use of peak amplitude, which measures one single time point, will 
not take into consideration current changes occurring before and after the time of the peak. 
Therefore, to compare the actual vs. predicted currents in a way that would more closely 
represents the current experienced by the cell, we measured the ionic charge conducted through 
each receptor by integrating the area under the current traces (Fig. 2-3). Our results measuring 
ionic charge confirmed our original findings using peak amplitude.  
In addition, these experiments also revealed the effect of lowering the concentration of 
one of the agonists on the desensitization of the actual combined current. As explained before, to 
calculate the ionic charge we reduced the concentration of ACh to 15µM (instead of 50µM), 
which resulted in an increase in the desensitization rate of the actual combined current (Fig. 2-
3A). These experiments suggest that 5HT3Rs are still functional in the actual combined currents 
but at 50µM ACh, the nAChRs are mostly responsible for the slower current kinetics.   
 
3.1.3 Cross-talk was Ca
2+
-independent 
 
To investigate whether Ca
2+ 
entry through both 5HT3Rs and nAChRs could participate in 
cross-talk mechanisms we designed experiments in Ca
2+
 free conditions, as previously described 
for synaptosomes (Dougherty and Nichols, 2009). In these experiments, 5HT3Rs and nAChRs 
inhibited each other’s function through Ca2+ions. However, our results showed that Ca2+ and 
Ca
2+
-dependent second messenger pathways were not involved in the mechanisms behind cross-
talk in the SCG (see Fig. 2-7). It is important to note that the type of receptors and their 
anatomical location are markedly different between the synaptosomes and the SCG, which may 
account for the difference in the cross-talk mechanisms. In the CNS, nAChRs mostly contain 4 
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subunits and they are located pre-synaptically where they are mainly involved in the regulation 
of neurotransmitter release. On the other hand, nAChRs in the PNS (particularly in the SCG) 
mostly contain 3 subunits and they are located post-synaptically where they drive autonomic 
synaptic transmission (reviewed by Hurst et al., 2013). Thus, these differences between the CNS 
and PNS may be essential for the type of regulation the nAChRs are subjected to. While Ca
2+
 is a 
key player during neurotransmitter release, and directly regulates the interaction between 
5HT3Rs and nAChRs at synaptosomes, other mechanisms could be more relevant for the 
interaction at sympathetic ganglia, including a physical interaction. 
   
3.1.4 The specificity of cross-talk to 5HT3Rs and nAChRs 
 
Since SCG neurons express multiple receptors that respond to both ACh and 5HT, to 
study the nature of the cross-talk mechanisms between these currents we used specific agonist 
and antagonists to isolate the currents mediated by solely nAChRs and 5HT3Rs.  
We used multiple methods to isolate currents through 5HT3Rs and nAChRs because 
pharmacological specificity among members of the Cys-loop family has been shown to be 
insufficient (Papke et al., 2004), something we have also observed in our own experiments (1µM 
MDL 72222 inhibits nAChRs, not shown). First we used the nAChR specific agonist nicotine 
and the 5HT3R specific agonist mCPBG (see Fig. 2-2C, 2-3C, 2-4C). Under these conditions we 
demonstrated that the actual current generated by the co-application of agonists was still 
significantly smaller than the calculated predicted current. These results suggested that the cross-
talk required nAChRs and 5HT3Rs.  
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Second, to isolate currents mediated through 5HT3Rs and nAChRs, we created a cocktail 
of antagonists that blocked metabotropic receptors sensitive to ACh and 5HT (Fig. 2-2E). These 
antagonists permitted us to use the endogenous agonists. These conditions also resulted in 
combined currents that were smaller than predicted, thus also suggesting that cross-talk required 
nAChRs and 5HT3Rs. 
Here, the use of agonists specific to 5HT3Rs and nAChRs, and antagonists that isolate 
currents by 5HT3Rs and nAChRs were able to show that cross-talk was specific to these two 
receptors. In fact, our findings indicated that cross-talk was even stronger when mCPBG was 
used (Fig. 2-2D, Fig. 2-3D, Fig. 2-4D). Thus, these data strongly suggest that the cross-talk 
mechanisms observed specifically involved 5HT3Rs and nAChRs.  
 
3.1.5 Does 5HT have a direct effect on nAChRs?  
 
To study whether 5HT3Rs were cross-talking with nAChRs, or vice versa, we designed 
experiments in which 5HT or mCPBG was applied in the middle of a prolonged ACh pulse (see 
Fig. 2-4). Unfortunately we could not do the opposite experiment, in which ACh was applied 
during a long 5HT pulse, because of the strong desensitization of the 5HT3R-mediated current. 
Our experiments confirmed that activation of 5HT3Rs during prolonged ACh-evoked currents 
induced not only a non-additive current, but also an inhibition of the ACh-evoked current. This 
effect was stronger in the case of mCPBG application (Fig. 2-4B). An interesting aspect of this 
inhibition is that it is inversely proportional to the amount of current that should be passing 
through the 5HT3R due to the activation by mCPBG. This aspect made us wonder if this effect 
was mediated by an alternative mechanism contributing to the interaction of the receptors but 
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independent of 5HT3Rs. To confirm this, we repeated the experiments in the presence of the 
5HT3R specific antagonists, MDL 72222 and Y25130 (Fig. 2-5). Surprisingly, under these 
conditions, 5HT still caused an inhibition of the ACh-evoked currents. These puzzling results 
raised the question whether in these conditions, where 5HT is applied during a prolonged ACh 
application, 5HT maybe acting directly on nAChRs without involving the function of 5HT3Rs.  
To address this possibility that 5HT directly acts on nAChRs, we repeated the 
experiments performed by Hu et al. (2007), who previously demonstrated that 5HT had a direct 
effect on nicotinic-evoked currents in sensory neurons. Our results were in stark contrast to what 
was published before (Fig. 2-6C). In SCG neurons, 5HT did not produce any changes in the dose 
response relationship of the ACh-evoked current suggesting that it did not have any direct effect 
on nAChRs, either competitive or non-competitive. A few reasons may explain this difference. 
First, our data comes from primary cultures from autonomic neurons, which may respond 
differently to 5HT than sensory neurons. Second, we used antagonists for m5HTRs and 
muscarinic ACh receptors in the generation of our ACh dose-response curve in the presence and 
absence of 5HT. It is worrying that these antagonists were omitted by Hu et al., particularly since 
some of the effects reported could be explained by metabotropic receptor function. Thus, we 
concluded from our own data that the 5HT3R did not directly interact with the nAChR. 
Note that the experiments presented in figure 2-6 do not support our findings with the 
prolonged ACh application experiments described above (Fig. 2-4). Here, 5HT may have been 
acting differently, perhaps directly, on nAChRs during the desensitization phase. This possibility 
needs to be addressed in future experiments where the potential direct effect of 5HT is tested 
using the prolonged ACh application protocol.  
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3.1.6 The physical interaction of 5HT3Rs and nAChRs 
 
So far our findings revealed that the cross-talk between 5HT and ACh-evoked currents do 
not require metabotropic receptors, Ca
2+
 ions or Ca
2+
-mediated 2
nd
 messenger pathways, or, at 
least in part, the direct effect of 5HT on nAChRs. Therefore, we next examined the possibility of 
physical interaction between the two receptors. This was a mechanism that had been previously 
described between P2X/nAChRs and P2X2/5HT3Rs (see section 2.1).   
To address this possibility of physical interaction, we performed experiments with an 
antibody against the M3-M4 linker of the 5HT3A subunit (Fig. 2-8). To increase the quantity of 
antibodies bound to the 5HT3A M3-M4 linker, we used a polyclonal antibody. Our preliminary 
results suggested that cross-talk inhibition between the 5HT3R and nAChRs depended on the 
availability of the M3-M4 linker of 5HT3A. These data suggested for the first time a modulation 
by 5HT3Rs on nAChRs in autonomic neurons mediated receptor-receptor interaction. However, 
further experiments need to be performed, increasing time and concentration of antibody 
incubation to ensure complete interference of the M3-M4 linker. In addition, these experiments 
should be done at 37°C instead of room temperature to ensure optimal antibody binding. 
 
3.2 Summary 
 
 The data summarized in this thesis showed for the first time a cross-talk inhibition of 
nAChRs driven by 5HT3Rs. This effect was not dependent on Ca
2+
, metabotropic receptors, or, 
at least in part, the direct inhibition of nAChRs by 5HT. In addition, this effect was specific to 
5HT3Rs and nAChRs. This novel inhibitory effect is relevant to understand autonomic 
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physiology, particularly since autonomic synaptic transmission is strictly driven by nAChRs, and 
therefore modulation of their function maybe important for both physiological and pathological 
conditions.   
 
3.3 Significance of Findings  
 
We have discussed earlier that understanding the neurotransmitters and receptors of the 
SNS was critical to knowing how it behaves in normal and pathological states. Yet, in the 
literature there was extremely little information on the role of 5HT and the 5HT3R in the SNS 
(1.1.3). This may be because the role of 5HT in the PNS was being overshadowed by its role in 
the CNS (Villalon and Centurion, 2007). Our work aimed to significantly advance knowledge on 
the role of 5HT and the 5HT3R in the modulation of nAChR, and therefore SNS function.  
The purpose of ACh release in the SCG is to induce fast autonomic synaptic transmission 
and generation of action potentials that could propagate to the target tissues. Thus, the 
modulatory effect of 5HT3Rs on the sympathetic tone, by cross-talk with nAChRs, suggests a 
potential role of 5HT on SNS physiology, for example reducing heart rate, blood pressure, and 
bronchodilation.  
In fact, evidence for 5HT3R regulation of the SNS had been found in vivo. In a model of 
orthostatic intolerance in rats, in which the heart responds pathologically to inversion by 
lowering heart rate instead of raising it, the administration of two 5HT3R specific antagonists, 
MDL 72222 and ondansetron recovered the rats’ abilities to increase heart rate (Martel et al., 
1998). Why or how blocking 5HT3Rs recovered the heart rate in this rat model was unknown, 
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and perhaps inhibition of nAChRs by 5HT3R by cross-talk in sympathetic ganglia may play a 
role in the decreased heart rate seen in orthostatic intolerance.  
In humans, 5HT3R antagonists are used frequently as an antiemetic during chemotherapy 
(see section 1.2.1). This pattern of use has produced documented cases of bradycardia associated 
with granisetron use on children (Buyukavci et al., 2005). Although, it is unclear if cross-talk 
between nAChRs and 5HT3Rs is involved, these findings further support a role for 5HT3Rs in 
the SNS. In addition, hypertension has also been linked to 5HT3R function through gLTP 
(Johnston, 1992; Brown and McAfee, 1982; Koyano et al., 1985), which can be prevented by the 
blockage of 5HT3Rs with specific antagonists (Alkadhi et al., 2001, 2005; Gerges et al., 2002). 
These reports demonstrate the complexity of 5HT3R function within the body, and the need for 
whole animal experiments to understand how 5HT3Rs modulate physiological function.  
The 5HT3R and its effects on the SNS may also be critical for pathological conditions 
that target the autonomic nervous system, such as diabetic autonomic neuropathy (see section 
1.1.4). Recently it was reported that the nAChR have a cysteine residue sensitive to oxidation 
(Campanucci et al., 2008; 2010), which is particularly targeted in diabetes by the glucose-
induced accumulation of ROS. Oxidation of nAChRs in diabetic mice leads to depression of 
autonomic function and serious dysautonomia. 5HT3Rs also contained an analogous region with 
a conserved cysteine residue, located in the intracellular M1-M2 in the same position as the 
nAChRs. Our own unpublished observations reveal that this receptor is also sensitive to ROS, 
which causes a fast and irreversible run-down that can be prevented by previous exposure to 
antioxidants. The latter might be significant for understanding the function of the SNS under 
pathological conditions. Thus, further experiments on this effect, and how it affects cross-talk 
with  
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3.4 Future Directions 
 
 The key question left unanswered within this work was the mechanism behind the cross-
talk of these receptors. We have thus far only been able to eliminate a few possibilities including 
Ca
2+
, direct ligand-receptor interaction, and metabotropic receptors. At this stage, the most likely 
mechanism is receptor-receptor interaction between nAChRs and 5HT3Rs. We have begun 
preliminary experiments probing the 5HT3A M3-M4 linker, but there are numerous other 
directions we can progress in. The most anticipated experiments we plan to do is the mutation of 
the M3-M4 linker of 5HT3A and expression of the nAChR and 5HT3R within Xenopus laevis 
oocytes. These experiments would effectively isolate the two LGICs from the many confounding 
factors found in native neurons, and would also allow identification of the molecular 
determinants responsible for cross-talk.  
Another issue we have considered, but have been unable to test was the possibility that 
the subunits of 5HT3R and nAChR were combining together to form a chimeric channel. This 
has been shown as a possibility between 5HT3A and α4 receptor subunits; at least when injected 
into X. laevis oocytes (van Hooft et al., 1998). The resulting chimeric channel was biphasic, 
responsive to 5HT, but not ACh. As described in section 1.2.2, the primary nAChR type 
expressed in SCG neurons was α3β4. Note that the same work by van Hooft et al. (1998) also 
tested the α3 subunit, which did not co-assemble with the 5HT3A subunit to form a functional 
channel. Therefore, a 5HT3A/α4 chimeric channel may form only a small portion of the total 
functional channels in SCG neurons. Nevertheless, given this possibility, it may be worth 
examining, especially when it becomes possible in our laboratory to use a system capable of 
expressing the neuronal nAChR.  
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3.5 Final Words 
 
 Here we show a cross-talk inhibition between the nAChRs and 5HT3Rs in mice SCG 
neurons. 5HT and ACh-induced currents were non-additive when the agonists were applied 
together. This interaction was also specific to the nAChRs and 5HT3Rs, as shown by the use of 
specific agonists, mCPBG (5HT3R) and nicotine (nAChR), and antagonists, MDL 72222 and 
Y25130 (5HT3R), methiothepin and asenapine (metabotropic 5HT receptors), and atropine 
(muscarinic receptors). It was also apparent that cross-talk inhibition did not depend on 5HT 
directly acting on the nAChR, although it could not be entirely discarded as an explanation in 
some experimental conditions. In addition to non-additive currents, it was also shown that 5HT 
induced depression in ACh-evoked current, which is physiological relevant for understanding the 
function of the sympathetic synapse. These results have many potential implications on SNS 
function in health and disease. Unfortunately, we have yet to discover the mechanism behind the 
cross talk. Further work will be necessary to complete the examination of the 5HT3R and 
nAChR interaction.  
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